Imlunestrant (novel oral SERD) was active in patients with an ESR1 mutations, but otherwise did not offer a benefit in this population of women with ER+ HER2-neg MBC. Overall survival (OS) data is pending with further follow up.
The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.
Improved progression-free survival (PFS), now we have osimertinib and ramucirumab, amivantamab and Lazertinib (PFS 24.8 vs 23 months but NOT head to head).
Ibrutinib delays disease progression for asymptomatic patients but has no overall survival (OS) benefit; hence, still watch and wait in those patients.
The addition of danicopan (factor D inhibitor) reduced extravascular hemolysis, so reduced anemia on those patients compared to ravulizumab or eculizumab.
Combination beat monotherapy is another option for MSI patients. Is combo better then pembro?
Another trial with neoadjuvant immunotherapy showing improved results over chemotherapy alone. (12% higher PCR 48% vs 36%).
FOLFOX is the way to go … as no significant difference was observed in the long-term survival outcome between mFOLFOX6 with and without radiation and fluorouracil plus radiation.
This is another option for gastric cancer that is showing efficacy in non-HER-2 neutrophils, as Enhertu showed superiority in a recent study in the second line over taxol and cyramza (destiny gastric 4).
Patients were treated with thoracic and extrathoracic radiation to oligometastatic sites and it seems to help with improving survival, something to consider especially with SBRT now. Do our radiation oncologists have additional input?
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
